Wall Street's Cardiac Bet: Where Diagnostics Meet the Money

The cardiovascular disease market is experiencing significant growth with U.S. heart disease costs projected to quadruple by 2050. The global AI cardiology market is expected to reach $14 billion by 2034, while interventional cardiology devices market will grow from $31.12 billion to $42.39 billion by 2031. Five major companies are advancing cardiac solutions: VentriPoint Diagnostics is expanding globally with regulatory submissions in China and new distribution partnerships; BridgeBio Pharma's acoramidis showed 44.7% reduction in all-cause mortality; Bristol Myers Squibb's Camzyos met primary endpoints in adolescent trials; Arrowhead Pharmaceuticals' plozasiran achieved 83% median triglyceride reduction; and Amgen's Repatha reduced cardiovascular event risk by 31% in primary prevention patients.

05/12/2026, 8:30 AM • Benzinga

Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

BridgeBio announced long-term efficacy data from the ATTRibute-CM trial showing acoramidis (Attruby) achieved a 44.7% reduction in all-cause mortality and 49.3% reduction in cardiovascular mortality at Month 54 compared to placebo. The drug demonstrated sustained clinical benefits including mitigation of NT-proBNP progression and maintained quality of life scores, with a favorable safety profile.

03/30/2026, 3:30 PM • GlobeNewswire

BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9

BridgeBio announced positive Phase 3 FORTIFY interim analysis results for BBP-418, an oral treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The drug showed early separation from placebo in ambulation tests at three months, with participants completing the 100-meter timed test approximately 31 seconds faster than placebo at 12 months. BBP-418 demonstrated a favorable safety profile comparable to placebo. The company plans to submit an NDA to the FDA in the first half of 2026, with a U.S. launch anticipated in late 2026/early 2027. If approved, BBP-418 could be the first approved therapy for LGMD2I/R9 and potentially the first for any form of LGMD.

03/11/2026, 2:00 PM • GlobeNewswire

BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz

BridgeBio Pharma stock surged 12.60% following William Blair's initiation of coverage with an Outperform rating and $93.03 price target. The analyst highlighted the company's accelerating Attruby launch, near-term NDA submissions for disease-modifying therapies, and a strong pipeline in rare genetic diseases including achondroplasia and autosomal dominant hypocalcemia. BridgeBio's products are positioned as next-generation alternatives to Pfizer's market-leading tafamidis.

03/10/2026, 2:49 PM • Benzinga

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma's compensation committee approved equity grants of 76,701 restricted stock units to 34 new employees on February 12, 2026. The grants vest over four years with one-fourth vesting after one year and the remainder vesting quarterly thereafter, subject to continued employment.

02/17/2026, 6:22 PM • GlobeNewswire

BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026

BridgeBio Pharma announced positive Phase 3 trial results for infigratinib in treating achondroplasia (dwarfism) in children, showing superior annualized height velocity compared to placebo. The company plans to submit FDA and regulatory applications in the second half of 2026. The stock surged 6.92% to $78.41, nearing its 52-week high.

02/12/2026, 12:44 PM • Benzinga

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?

The biotech sector rebounded strongly in 2025 as M&A activity surged, becoming a stabilizing force for small and mid-cap companies. With 57% of biopharma acquisitions involving smaller firms and $30.9 billion in deals, investor sentiment shifted from GLP-1 drugs toward cancer and autoimmune disease treatments, particularly next-generation CAR-T therapies. Looking ahead to 2026, analysts expect continued M&A activity and strategic partnerships, though risks remain including FDA staff turnover and an 'IPO air pocket' from the 2023-2024 downturn.

12/31/2025, 10:01 AM • Benzinga

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

BridgeBio Pharma presented data from the ATTRibute-CM study showing acoramidis significantly reduces all-cause mortality in variant ATTR-CM populations, with a 69% risk reduction in mortality for patients with the V142I genetic variant.

11/08/2025, 10:41 AM • GlobeNewswire

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

The National Advertising Division will refer BridgeBio Pharma to government agencies after the company failed to participate in an NAD inquiry regarding claims about its Attruby medication's superiority over Pfizer's Vyndamax.

11/07/2025, 1:00 PM • GlobeNewswire

BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study

BridgeBio Pharma announced successful Phase 3 trial results for BBP-418, a potential treatment for limb-girdle muscular dystrophy type 2I/R9, showing significant improvements in muscle function, glycosylation, and reduced muscle damage markers.

10/27/2025, 7:00 AM • GlobeNewswire

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

BridgeBio Pharma presented data from the ATTRibute-CM study showing acoramidis reduces cardiovascular outcomes in ATTR-CM patients, with significant risk reduction observed as early as the first month of treatment and sustained through 30 months.

09/28/2025, 11:15 AM • GlobeNewswire

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

BridgeBio's encaleret demonstrated promising results in a Phase 2 study for post-surgical hypoparathyroidism, with 80% of participants achieving normal blood and urine calcium levels within 5 days of treatment, leading to plans for a registrational clinical study in 2026.

09/06/2025, 2:30 PM • GlobeNewswire

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

BridgeBio Pharma presented data from the ATTRibute-CM open label extension study showing acoramidis reduced cardiovascular mortality by 44% in ATTR-CM patients over 42 months, demonstrating potential long-term clinical benefits for treating transthyretin amyloid cardiomyopathy.

08/30/2025, 7:15 AM • GlobeNewswire

Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics

Helix Acquisition Corp. II announced retaining approximately $120 million in its trust account, representing over 60% of cash, in connection with a business combination with BridgeBio Oncology Therapeutics. The transaction is expected to raise $382 million in gross proceeds, including $261 million from a private placement.

08/06/2025, 7:33 AM • Benzinga

KRAS Inhibitors Market Size Clinical Trials Patent Approved Drugs Sales Insight

The global KRAS inhibitors market is experiencing significant growth, with four approved drugs targeting KRAS mutations in cancers like lung, colorectal, and pancreatic. Over 80 drugs are in clinical trials, with promising developments in targeted cancer therapies.

07/09/2025, 10:58 AM • GlobeNewswire